Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
Figure 7
Presence and persistence of the scAb GLAF-1 and GusA in serum (A, B) and tumors (C, D) of GLV-1h109-injected xenograft mice at different time points. A, B:
Blood samples were collected at day 7, 14, 21 and 28 from (A) STSA-1 and (B) DT08/40 tumor bearing mice (n = 6). Expression of GLAF-1 in sera was quantitatively determined using ELISA. GLAF-1 values shown (bars) are mean + SD. GusA activity (represented by lines) was measured by detecting the activation of the fluorogenic compound FDGlcU. C: The presence of GLAF-1 in tumor tissue monitored by Western Blot. STSA-1 and DT08/40 tumor-bearing mice injected with GLV-1h109 were sacrificed on day 35 and day 49, respectively. Tumors were collected, and protein fractions from tumor lysate were separated by SDS/PAGE. Western blot analysis was performed using an anti-DDDK antibody. D: Localization of GLAF-1 protein in virus-infected STSA-1 tumor areas. Overlays represented the virus infection GFP fluorescence (green)/presence of GLAF-1 (red). Scale bars, 500 µm. (200× magnification).